LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LAVA Therapeutics NV
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Other Equity
-$10.9m
CAGR 3-Years
-122%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Other Equity
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Other Equity
€26.6m
CAGR 3-Years
-1%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Other Equity
-$56.7m
CAGR 3-Years
-47%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Other Equity
$128.9m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Other Equity
-$7.1m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Other Equity?
Other Equity
-10.9m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Other Equity amounts to -10.9m USD.

What is LAVA Therapeutics NV's Other Equity growth rate?
Other Equity CAGR 3Y
-122%

Over the last year, the Other Equity growth was 16%. The average annual Other Equity growth rates for LAVA Therapeutics NV have been -122% over the past three years .

Back to Top